Abstract:

This investigation into the barriers and facilitators influencing the adoption of HIV Pre-Exposure Prophylaxis (PrEP) among at-risk and general populations in Regions 3, 4, and 10 of Guyana is of substantial significance. Employing a questionnaire administered to 280 participants, this research explores demographic characteristics, knowledge levels, and perceived obstacles to PrEP accessibility. The findings reveal a gender distribution of male participants (51%), with a notable representation of non-binary individuals (11%). While 60% of respondents have considered utilizing PrEP, the study highlights critical barriers, including stigmatization (50%), insufficient awareness (36%), and affordability concerns (32%). Confidence in PrEP knowledge varies, with only 25% of participants expressing moderate confidence. Healthcare providers play a pivotal role in decision-making for 69% of respondents, indicating the importance of provider-patient interactions in influencing PrEP uptake. This study emphasizes the necessity for targeted awareness campaigns, enhanced healthcare provider education, and the establishment of dedicated PrEP clinics to address these barriers. By identifying and addressing these challenges, this research aims to inform strategies that augment PrEP uptake, ultimately reducing new HIV infections and improving public health outcomes in Guyana.

References:

[1]. World Health Organization, HIV - Global [Internet]. 2019, Oct 1, [cited 2024 Feb 17]. Available from: https://www.who.int/health-topics/hiv-aids#tab=tab_1.

[2]. World Health Organization, HIV Data and Statistics [Internet]. 2024, Mar 1, [cited 2024 Feb 17]. Available from: https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hiv/strategicinformation/hiv-data-and-statistics.

[3]. World Health Organization, Pre-Exposure Prophylaxis (PrEP) [Internet], 2024, Mar 1, [cited 2024 Feb 17]. Available from: https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hiv/prevention/pre-exposure-prophylaxis.

[4]. U.S. Food and Drug Administration, FDA approves first drug for reducing the risk of sexually acquired HIV infection [Internet]. 2012, [cited 2024 Feb 17]. Available from: https://www.fda.gov.

[5]. U.S. Food and Drug Administration, FDA approves second drug to prevent HIV infection as part of ongoing efforts to end the HIV epidemic [Internet]. 2019, [cited 2024 Feb 17]. Available from: https://www.fda.gov.

[6]. Mayer, K. H., Agwu, A., Malebranche, D., 2020, Barriers to the wider use of pre-exposure prophylaxis in the United States: A narrative review. Adv Ther. 37(5):1778-811. doi: 10.1007/s12325-020-01295-0.

[7]. World Health Organization, 2016, Consolidated guidelines on HIV prevention, diagnosis, treatment, and care for key populations - 2016 update [Internet]. [cited 2024 Feb 17]. Available from: https://www.who.int/publications/i/item/9789241511124.

[8]. National AIDS Program Secretariat, National AIDS Program Secretariat Annual Report. 2022.

[9]. Antonini, M., Da Silva, I. E., Elias, H. C., Gerin, L., Cunha-Oliveira, A., Reis, R. K., 2023 Barriers to pre-exposure prophylaxis (PrEP) use for HIV: An integrative review. Rev Bras Enferm. 76(3). doi: 10.1590/0034-7167-2021-0963.

[10]. World Health Organization, Global State of PrEP [Internet]. n.d. [cited 2024 Feb 17]. Available from: https://www.who.int/groups/global-prep-network/global-state-of-prep#:~:text=There%20were%20about%201.6%20million,in%20eastern%20and%20southern%20Africa.

[11]. Bureau of Statistics, Guyana. Demography, vital, and social statistics [Internet]. n.d. [cited 2024 Feb 17]. Available from: https://statisticsguyana.gov.gy/subjects/demography-vital-and-social-statistics/.

[12]. Cohen, L., Manion, L., Morrison, K., 2017, Research methods in education. 8th ed. Abingdon: Routledge.

[13]. Nabunya, R., Karis, V. M. S., Nakanwagi, L. J., et al., 2023, Barriers and facilitators to oral PrEP uptake among high-risk men after HIV testing at workplaces in Uganda: A qualitative study. BMC Public Health. 23:365. doi: 10.1186/s12889-023-15260-3.

[14]. Dolling, D. I., Phillips, A. N., Delpech, V., Miltz, A., Pozniak, A., McCormack, S., 2016, An analysis of baseline data from the PROUD study: An open-label randomized trial of pre-exposure prophylaxis. Trials. 17(1):163. doi: 10.1186/s13063-016-1286-4.

[15]. Centers for Disease Control and Prevention. Vital signs: Increased Medicaid prescriptions for pre-exposure prophylaxis against HIV infection — New York, 2012–2015. Morb Mortal Wkly Rep. 2015;64(46).